Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 29th 2016

Healthcare Utilization in Children With Sickle Cell Disease

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, researchers from the Aflac Cancer and Blood Disorders Center presented analysis evaluating the factors that influence health outcomes in children with sickle cell disease.

January 29th 2016

5 Things to Know About Clinical Pathways

Surabhi Dangi-Garimella, PhD

Learn where clinical care pathways stand today and what the future holds with respect to developing and implementing them.

January 28th 2016

FDA Advocates for Diversity in Clinical Trials

Surabhi Dangi-Garimella, PhD

The FDA has created the Drug Trial Snapshot, which provides details on the demographic profiles of participants in clinical trials of approved drugs.

January 28th 2016

Three Proposals That Would Kill the 340B Program

Robert Chapman, MD

The 3 prescriptions for reforming the 340B Drug Discount Program proposed by authors in the December issue of Evidence-Based Oncology would limit safety net hospitals' abilities to treat vulnerable patients.

January 28th 2016

Nivolumab Improved OS in SCCHN; CheckMate-141 Stopped Early

Surabhi Dangi-Garimella, PhD

A review by an independent Data Monitoring Committee found that nivolumab improved overall survival in patients with squamous cell carcinoma of the head and neck, compared with the control arm.

January 27th 2016

Study Shows Academic Hospitals Better at Caring for ALL Patients

Surabhi Dangi-Garimella, PhD

A study presented during a health outcomes session at the American Society of Hematology meeting evaluated the difference in overall survival in patients with acute lymphoblastic leukemia treated in academic versus nonacademic hospitals.

January 27th 2016

Insurance Status Determines OS in Patients With CML

Surabhi Dangi-Garimella, PhD

Results presented at the annual meeting of the American Society of Hematology found that many patients diagnosed with chronic myeloid leukemia may not have access to or receive appropriate care, in part due to their insurance coverage.

January 27th 2016

Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease

Surabhi Dangi-Garimella, PhD

Results from a patient-reported outcomes measure of symptoms and symptom burden, experienced by patients with acute myeloid leukemia and myelodysplastic syndrome, were presented at the 57th annual meeting of the American Society of Hematology.

January 27th 2016

Smoking Can Reduce Survival of Breast Cancer Patients

Surabhi Dangi-Garimella, PhD

A study published in the Journal of Clinical Oncology has found that smoking before and after diagnosis of breast cancer is associated with increased mortality from breast cancer as well as other conditions, including respiratory and cardiovascular disease.

January 27th 2016

Study Finds Strongest Link Yet Between Tanning Beds and Cancer, Especially Among Teens

The FDA seeks a nationwide ban on indoor tanning among those under 18. Right now, a patchwork of laws bar teens from indoor tanning in some states and require parental consent in others.

January 26th 2016

Personalizing Healthcare and Also Paying for It

Surabhi Dangi-Garimella, PhD

Personalized medicine has been the mantra in healthcare for quite some time, but finding health plans with blanket coverage policies for diagnostic testing is a struggle.

January 25th 2016

How Do You Develop, and Successfully Incorporate, PROs in Hematology? Experts Chime in at ASH

Surabhi Dangi-Garimella, PhD

An educational session on Patient-Reported Outcomes in Hematology at the annual meeting of the American Society of Hematology, discussed the importance of embracing the patient perspective in healthcare delivery.

January 25th 2016

Experts Share Concepts of Quality Measures and Pay-for-Performance With Hematologists

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, experts discussed quality measurement, public performance reporting, and pay-for-performance and it's impact on healthcare in the United States.

January 25th 2016

ASH Leverages Recommendations From Other Medical Organizations, Advising Hematologists to Choose Wisely

Surabhi Dangi-Garimella, PhD

Thirteen hematologists on the American Society of Hematology(ASH)'s Choosing Wisely Task Force chose the top 5 of 380 recommendations listed by 70 other societies for presentation at ASH.

January 25th 2016

Cancer Study Recommends Lowering CRC Screening Age

Surabhi Dangi-Garimella, PhD

The authors of the study recommend lowering the screening age for colorectal cancer (CRC), especially for first-degree relatives of CRC patients and those with a genetic predisposition to the disease.

This Week in Managed Care: January 23, 2016

January 23rd 2016

This Week in Managed Care: January 23, 2016

Top managed care stories this week included UnitedHealth reporting larger-than-expected losses on Affordable Care Act health plans, new guidelines from the government that will improve patient access to medical records, and new information that can reduce risk of diabetes.

Dr Kavital Patel Examines Accounting for Drug Costs in Total Cost of Care

January 23rd 2016

Dr Kavital Patel Examines Accounting for Drug Costs in Total Cost of Care

Kavita Patel, MD, fellow in economic studies and managing director at Brookings Institution, discussed how the cost of drugs should be accounted for in the total cost of care, and the importance of considering patient needs when offering drugs.

January 22nd 2016

How Much Will Amgen's Carfilzomib for Multiple Myeloma Cost?

Surabhi Dangi-Garimella, PhD

Carfilzomib has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

January 21st 2016

Abundant Optimism at the ASH/FDA Joint Symposium on New Drug Approvals in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

At a joint session at the annual meeting of the American Society of Hematology, primary clinical reviewers from the FDA discussed the safety and efficacy issues of 3 very recently approved drugs for multiple myeloma, along with 2 clinicians who have extensive experience with these drugs in the real-world setting.

January 21st 2016

New Hematology Drugs: Progress and Challenges Discussed at the 57th ASH Meeting

Surabhi Dangi-Garimella, PhD

A session on the first day of the annual meeting of the American Society of Hematology, held December 5-8, 2015, in Orlando, Florida, clinicians discussed the promise and challenges of using newly approved hematology/oncology agents.

January 21st 2016

Nonrecommended Cancer Screening Rates Remain High Among Individuals With Limited Life Expectancy

Surabhi Dangi-Garimella, PhD

An estimated 15.7% of individuals 65 or older may have received nonrecommended screenings for prostate and breast cancer, according to a new study published in JAMA Oncology.

January 21st 2016

ED-Initiated Palliative Care Can Improve Quality of Life

Palliative care initiated in the emergency department for patients with advanced cancer improves quality of life without shortening survival.

January 21st 2016

Indoor Tanning Among Teens Associated With Drug Use, Study Finds

The study found a stronger association than researchers expected; it appears that risky behavior in one area implies risky behavior elsewhere.

January 21st 2016

Novel Combinations in Multiple Myeloma and Lymphoma

Michael R. Page, PharmD, RPh Surabhi Dangi-Garimella, PhD

At the 57th annual meeting of the American Society of Hematology, oncologists discussed trial data evaluating combination therapies for multiple myeloma and lymphoma.

January 20th 2016

Study Narrows Time to Surgery Following Chemoradiotherapy in Rectal Cancer

Surabhi Dangi-Garimella, PhD

A retrospective analysis of data from the National Cancer Data Base has found that patients who had cancer surgery at 56 days after the end of combined chemoradiotherapy presented with the best overall survival and successful removal of their residual tumors.

January 20th 2016

Who Should Lead the Shared-Care Cancer Survivorship Model?

Surabhi Dangi-Garimella, PhD

A study presented at the 2016 Cancer Survivorship Symposium hosted by the American Society of Clinical Oncology has identified significant uncertainty on who is responsible for the care of cancer survivors.

January 20th 2016

Rule Says Hospitals, Providers Must Give Patients Access to Records

The new rule has implications for personalized medicine, because having access to records helps tailor treatments for everything from cancer to chronic conditions.

January 19th 2016

Family Members Prefer Compassionate End-of-Life Care for Cancer Patients

Surabhi Dangi-Garimella, PhD

The results of a new JAMA study underscore the importance of advance care planning in improving the quality of care that patients receive at the end of life.

January 19th 2016

The Least (and Most) Expensive States to Be a Smoker

A review of WalletHub's list of the least expensive states to smoke shows there's a definite relationship between the cost of lighting up and high rates of smoking among adults, based on CDC data.

January 19th 2016

Kool Aid and Gummi Bear e-Cigarettes: Is the Target Population Changing?

Surabhi Dangi-Garimella, PhD

A new study from England has found that advertisements that promote e-cigarettes with flavors such as chocolate and bubble gum are more likely to attract school children to buy and try e-cigarettes.

...

111 112 113 114 115 116 117 118 119

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions